Industry's role in HIV, hepatitis B, and hepatitis C exclusion in AML and MDS clinical trials

Hematology. 2023 Dec;28(1):2254558. doi: 10.1080/16078454.2023.2254558.

Authors

Tahsin Anwar¹, Sean Malhotra², Mohammad A H Mian^{3

4}, Tahiya Anwar³, Vamsi Kota^{1

3

4

5}, Mahran Shoukier⁵

Affiliations

¹ Augusta University, Augusta, Georgia.
² Emory University, Atlanta, Georgia.
³ Augusta University Medical Center, Augusta, Georgia.
⁴ Georgia Cancer Center, Augusta University, Augusta, Georgia.
⁵ Medical College of Georgia, Augusta University, Augusta, Georgia.

PMID: 37680035
DOI: 10.1080/16078454.2023.2254558

No abstract available

MeSH terms

HIV Infections* / complications
HIV Infections* / drug therapy
Hepatitis B* / complications
Hepatitis B* / drug therapy
Hepatitis C* / complications
Hepatitis C* / drug therapy
Humans
Leukemia, Myeloid, Acute*